Thermo Fisher Scientific TWEAK Polyclonal Antibody, Biotin, PeproTech

Applications and Tested Dilution

Product Specifications

Product Specific Information

AA Sequence of recombinant protein:
MKGRKTRARR AIAAHYEVHP RPGQDGAQAG VDGTVSGWEE ARINSSSPLR YNRQIGEFIV TRAGLYYLYC QVHFDEGKAV YLKLDLLVDG VLALRCLEEF SATAASSLGP QLRLCQVSGL LALRPGSSLR IRTLPWAHLK AAPFLTYFGL FQVH

Preparation:
Produced from sera of goats immunized with highly pure Recombinant Human TWEAK. Anti-Human TWEAK-specific antibody was purified by affinity chromatography and then biotinylated.

Sandwich ELISA:
To detect Human TWEAK by sandwich ELISA (using 100 µL/well antibody solution), a concentration of 0.25–1.0 µg/mL of this antibody is required. This biotinylated polyclonal antibody, in conjunction with PeproTech Polyclonal Anti-Human TWEAK (500-P137G) as a capture antibody, allows the detection of at least 0.2–0.4 ng/well of Recombinant Human TWEAK.

Western Blot:
To detect hTWEAK by Western Blot analysis, this antibody can be used at a concentration of 0.1–0.2 µg/mL. Used with compatible secondary reagents, the detection limit for Recombinant hTWEAK is 1.5–3.0 ng/lane under either reducing or non-reducing conditions.

Packaging:
500-P137GBT-1MG will be provided as 2 × 500 µg.

Target Information

TNF-related weak inducer of apoptosis (TWEAK) is a member of the tumor necrosis factor superfamily (TNFSF) of structurally related cytokines. Like most other members of this family, TWEAK is a cell surface-associated type II transmembrane protein, although a smaller, biologically active form can also be generated by cleavage near the cell membrane. TWEAK has multiple biological activities, including stimulation of cell growth and angiogenesis, induction of inflammatory cytokines, and stimulation of apoptosis. The TWEAK signal transduction pathway appears to signal via TweakR/Fn14 similarly to other TNFSF members that bind receptors lacking death domains.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.